[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"survival-prosthesis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:survival-prosthesis":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,40,63],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100502179","multicenter-mpact-dm-france-100502179",false,"NCT05818891","Multicenter Mpact DM France","Prospective, Multicenter, Non-Controlled, Non-Randomized, Open-Label Study To Evaluate The Efficacy And Performance Of The Mpact® Dual Mobility Hemispheric Cup","Inclusion Criteria:\n\n1. Patient with a disease that meets the indications for use of Medacta implants (according to the instructions for use)\n2. Patient eligible for first-line total hip replacement\n3. Patient between 18 and 80 years of age\n4. Patient covered by the Social Security system or an equivalent protection plan\n5. Patient who is capable, in the opinion of the investigator, of fulfilling the requirements of the study\n\nExclusion Criteria:\n\n1. Patient requiring a transplant\n2. Patient with progressive local or systemic infection\n3. Patient with muscle loss, neuromuscular disease, or vascular impairment of the affected limb making surgery unwarranted\n4. Patient with known medical problems that may compromise independent recovery of mobility\n5. Patient with a BMI greater than 40 kg\u002Fm².\n6. Patient with major cognitive problems that do not allow a good understanding of the study requirements\n7. Patient living in a geographical area that does not allow the study follow-up\n8. Patient participating in interventional research.\n9. Minor patient\n10. Protected adult patient\n11. Vulnerable person according to article L1121-6 of the Public Health Code\n12. Pregnant or nursing woman.","ALL","18 Years","80 Years",{"count":20,"type":21},600,"ESTIMATED","OBSERVATIONAL","The primary objective of the study is to evaluate the 10-year performance of the MPACT DM cup in the treatment of patients requiring total hip arthroplasty.\n\nThe primary endpoint is the 10-year life span of the prosthesis according to the Kaplan Meier curve.",[25,26],"Total Hip Arthroplasty","Survival, Prosthesis","RECRUITING","2025-09-23",{"date":30,"type":31},"2025-09-29","ACTUAL",{"date":33,"type":31},"2018-04-05",{"date":35,"type":21},"2031-04",{"name":37,"class":38},"Medacta International SA","INDUSTRY",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":46,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":48,"conditions":49,"keywords":4,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":4},"100589829","long-term-survival-of-tha-after-pelvic-andor-femoral-osteotomy-100589829","NCT06959498","Long-term Survival of THA After Pelvic and\u002For Femoral Osteotomy","Inclusion Criteria:\n\n* patients who underwent THA between 1998 and 2010 and had a prior surgical treatment for hip dysplasia (pelvic, femoral osteotomy, shelf acetabuloplasty or combined osteotomy)\n\nExclusion Criteria:\n\n\\-",{"count":47,"type":21},20,"Analyze the long-term clinical and radiological outcomes of total hip arthroplasty (THA) in patients with hip dysplasia treated by pelvic osteotomy, femoral osteotomy, shelf acetabuloplasty, or a combination of these interventions, performed during childhood or early adulthood. The aim is to understand the impact of these early interventions on THA survival and long-term joint function.",[50,51,26],"Hip Arthropathy Associated With Other Conditions","Hip Dysplasia","NOT_YET_RECRUITING","2025-04-28",{"date":55,"type":31},"2025-05-06",{"date":57,"type":21},"2025-05-01",{"date":59,"type":21},"2025-06-01",{"name":61,"class":62},"Central Hospital, Nancy, France","OTHER",{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":4,"eligibilityCriteria":69,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":70,"targetDuration":4,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":39},"100554526","phase-3-nutrition-impact-on-immunotherapy-of-cancer-100554526","NCT06500234","Nutrition Impact on Immunotherapy of Cancer","Phase III Study on the Relation of Nutrition and Immunotherapy of Cancer Patients","Inclusion Criteria:\n\n* Diagnosis of cancer, malnutrition Age \\>18 years Performance status ECOG of 0 or 2. Life expectancy ≥ 6 months. At least one lesion measurable as defined by standard imaging criteria for the patient's tumor type (RECIST v1.1) Patients must have normal organ and bone marrow function measured within 28 days prior to administration of study treatment Postmenopausal or evidence of non-childbearing status for women of childbearing potential Patient is willing and able to comply with the protocol for the duration of the study.\n\nFor all oral medications patients must be able to comfortably swallow capsules;\n\nExclusion Criteria:\n\n* Patients unable to swallow orally administered medication and patients with Impairment of gastrointestinal (GI) function or GI disease that may significantly alter drug absorption of oral drugs History of allogenic organ, bone marrow or double umbilical cord blood transplantation.\n\nActive or prior documented autoimmune or inflammatory disorders Uncontrolled intercurrent illness or patient considered a poor medical risk due to a serious, uncontrolled medical disorder, including but not limited to, ongoing or active infection, symptomatic congestive heart failure Currently taking medications with known risk of prolonging the QT interval or inducing Torsades de Pointes.",{"count":71,"type":21},300,"INTERVENTIONAL",[74],"PHASE3","This study investigates nutritional status and outcomes of immuntherapy in cancer patients.",[77,78,79,26],"Nutrition Disorders","Immunotherapy","Cancer","2024-07-12",{"date":82,"type":31},"2024-07-15",{"date":84,"type":31},"2024-06-01",{"date":86,"type":21},"2027-05-31",{"name":88,"class":62},"Qingdao Central Hospital"]